The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Hiroyuki Uetake
Speakers' Bureau - Bayer; Chugai Pharma; Sanofi; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Katsuya Tsuchihara
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Miyarisan pharmaceutical; Novartis; Novartis; Takeda
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Jun Watanabe
Speakers' Bureau - Medtronic
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takeo Sato
No Relationships to Disclose
 
Takeshi Naitoh
Honoraria - Chugai Pharma; Johnson & Johnson; Lilly; Medtronic; Proceed; Sumitomo Chemical; Taiho Pharmaceutical; Takeda; TERUMO
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); Daiichi Sankyo; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Ikuo Mori
Employment - Takeda
 
Kazunori Yamanaka
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Masamitsu Hihara
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Junpei Soeda
Employment - Takeda
 
Takeharu Yamanaka
Honoraria - Bayer; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - Gilead Sciences; HUYA Bioscience International; Sysmex
Research Funding - Bayer (Inst); Chugai/Roche (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kiwamu Akagi
No Relationships to Disclose
 
Atsushi Ochiai
No Relationships to Disclose
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)